

# DIAGNOSING FEVER IN RETURNING TRAVELERS -RECOMMENDATIONS FROM THE BEDSIDE AND LABORATORY

CARLOS DEL RIO, M.D., MCAP, FIDSA  
D. JANE HATA, PH.D., D(ABMM)

# LEARNING OBJECTIVES

- Three illustrative cases of fever in travelers
- Standard of care tests
- Esoteric tests
- New diagnostic approaches
  - Syndromic NAAT panels
- Laboratory workflow



1

# **CASE DESCRIPTION**

# CASE # 1

- A 52 y/o women originally from Nigeria returned from a one-month trip in which she visited family and friends that live predominantly in the Borno State in the North-East region of the country.
- She did not take malaria prophylaxis as she grew up in Nigeria and “there was never a need to take medicines”.
- States that as she was getting on the plane to return to the U.S., she started to have chills and later had fevers.
- Since then, she notes having daily evening fevers to 39 – 40°C. She feel tired and has a bad headache.
- Went to a local clinic and was prescribed Acetaminophen which she has taken without improvement.
- On physical exam she is afebrile, her HR is 110 and her BP in 140/70. On exam she is pale, in mild distress and has a palpable spleen tip.
- Laboratory finding include mild anemia and elevated liver enzymes.

# TRAVEL HISTORY IS KEY!

- Estimated that 8% of travelers require medical care
  - 30% require hospitalization
- When did travel occur?
  - Variable incubation periods
- Type of travel and duration
  - Urban?
  - Rural?
  - Ecotourism/Adventure tourism?
  - Other exposures (animals, plants, insects, food, water)?
- Sexual exposures
- Refugee/Migrant status
- Onset and nature of symptoms
  - Duration of fever
  - Other symptoms



Sondén K et al. Travel Med Infect Dis. 2025 May-Jun;65:102861.  
Thwaites GE, Day NP. N Engl J Med. 2017 Feb 9;376(6):548-560.

# INITIAL LABORATORY TESTING

- CBC and differential
- Liver enzymes
- Blood cultures
- Blood smear for malaria and/or rapid antigen diagnostic test (RDT)
  - RDT must be confirmed by smear
- Lumbar puncture and CSF analysis
- Other imaging
- Patient presentation and history will drive additional testing
  - Diarrhea, respiratory symptoms, rash, jaundice

Thwaites GE, Day NP. N Engl J Med. 2017 Feb 9;376(6):548-560.  
Wu HM. Semin Diagn Pathol. 2019 May;36(3):197-202.



**“THINK HORSES, NOT ZEBRAS”**

**-Dr. Theodore Woodward, Univ of Maryland**


# MOST LIKELY PATHOGENS; “THE HORSES”

## Most Common

- Malaria
  - Species related to geography
- Dengue Fever
- EBV
  - Mononucleosis
- Rickettsial infections
  - Typhus, RMSF, ehrlichosis, *Anaplasma*
- *Salmonella enterica*
  - Serotype typhi, paratyphi
  - Enteric fever
- “Other viral infections”

## Also Consider

- Influenza
- Sars CoV-2
- ETEC
- Zika
- Chikungunya
- MDR bacteria
- TB
- Regional outbreaks



<https://www.uptodate.com/contents/evaluation-of-fever-in-the-returning-traveler>


Brown AB, et al. MMWR Surveill Summ. 2023 Jun 30;72(7):1-22.



# CASE #1 - MALARIA

- **Most likely cause of fever in travelers**
  - *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae*
- Laboratory should have ability to screen STAT
  - Thick and thin smears
  - Detection of other pathogens (*Babesia*, *Ehrlichia*, Trypanosomes)
- Speciation from thin smears
  - Calculation of percent parasitemia
- Rapid antigen tests
  - Lateral flow immunochromographic method
    - 1 test FDA approved for use
  - Low sensitivity at  $\leq 200$  parasites/microliter
- NAATs
  - Not widely available, may not be STAT test


Thwaites GE, Day NP. N Engl J Med. 2017 Feb 9;376(6):548-560.



Christmas Eve 2024

# LABORATORY ALGORITHM FOR MALARIA

- Smears still considered gold standard
  - Repeat every 6-8 hours for up to 3 days
- Speciation critical for clinical management
- Quantification
  - Severe malaria  $\geq 5\%$  parasitemia
- RDT requires smear confirmation
- NAATs require smear confirmation for % parasitemia



# LESS LIKELY PATHOGENS; “THE ZEBRAS”

- Viral infections

- Measles
- Viral hemorrhagic fevers
  - Ebola
  - Marburg
- Rabies
- WNV
- Mpox
- Oropouche

- Parasitic infections

- Leishmaniasis
- Various helminths
- *Entamoeba histolytica*

- Bacterial infections

- Brucellosis
- Tetanus
- Melioidosis
- Q Fever

- US Travel

- Plague
- Babesiosis
- *Coccidioides immitis/posadasii*
- Ehrlichiosis/Anaplasmosis
- Hantavirus

- Emerging pathogens



# TYPES OF TESTS AVAILABLE

## -WHAT CAN YOUR LAB DO?



### Culture/Microscopy

- Bacterial ID
  - Phenotypic
  - MALDI-TOF
- AST methods
- Ova and Parasite exam
- Malaria smears



### Serology

- Antibody detection
- Antigen detection
- Immuno-chromatographic
  - Lateral-flow devices
- Immunoassay
  - Automation



### Molecular

- NAATs
  - LDTs
- Single analyte
- Multiplex
- Syndromic panels
- NGS

# SYNDROMIC TESTING NAAT PANELS POST-TRAVEL

## -ARE THESE USEFUL?

### Respiratory

- Adenovirus
- Coronavirus 229E, HKU1, NL63, OC43
- SARS-CoV-2
- HMPV
- Human Rhinovirus/Enterovirus
- Influenza A virus
- Influenza A virus A/H1
- Influenza A virus A/H3
- Influenza A virus A/H1-2009
- Influenza B virus
- RSV
- *Bordetella parapertussis*
- *Bordetella pertussis*
- *Chlamydia pneumoniae*
- *Mycoplasma pneumoniae*

### Gastrointestinal

- Astrovirus
- Adenovirus F40/41
- Norovirus GI/GII
- Rotavirus A
- Sapovirus (I, II, IV, and V)
- *Campylobacter* (*C. jejuni* / *C. coli* / *C. upsaliensis*)
- *Clostridioides* (*Clostridium*) *difficile* (toxin A/B)
- *Plesiomonas shigelloides*
- *Salmonella*
- *Yersinia enterocolitica*
- *Vibrio* (*V. parahaemolyticus* / *V. vulnificus* / *V. cholerae*)
- EAEC, EPEC, ETEC, STEC EIEC
- *Cryptosporidium*
- *Cyclospora cayetanensis*
- *Entamoeba histolytica*
- *Giardia lamblia*

### Meningitis/Encephalitis

- CMV
- Enterovirus
- HSV 1,2
- HHV-6
- Human parechovirus
- VZV
- *Escherichia coli* K1
- *Haemophilus influenzae*
- *Listeria monocytogenes*
- *Neisseria meningitidis*
- *Streptococcus agalactiae*
- *Streptococcus pneumoniae*
- *Cryptococcus* (*C. neoformans*/ *C. gattii*)

# SYNDROMIC TESTING NAAT PANELS POST-TRAVEL

## -ARE THESE USEFUL?

### Respiratory

- Adenovirus
- Coronavirus 229E, HKU1, NL63, OC43
- SARS-CoV-2
- HMPV
- Human Rhinovirus/Enterovirus
- Influenza A virus
- Influenza A virus A/H1
- Influenza A virus A/H3
- Influenza A virus A/H1-2009
- Influenza B virus
- RSV
- *Bordetella parapertussis*
- *Bordetella pertussis*
- *Chlamydia pneumoniae*
- *Mycoplasma pneumoniae*

### Gastrointestinal

- Astrovirus
- Adenovirus F40/41
- Norovirus GI/GII
- Rotavirus A
- Sapovirus (I, II, IV, and V)
- *Campylobacter* (*C. jejuni* / *C. coli* / *C. upsaliensis*)
- *Clostridioides* (*Clostridium*) *difficile* (toxin A/B)
- *Plesiomonas shigelloides*
- *Salmonella*
- *Yersinia enterocolitica*
- *Vibrio* (*V. parahaemolyticus* / *V. vulnificus* / *V. cholerae*)
- EAEC, EPEC, ETEC, STEC EIEC
- *Cryptosporidium*
- *Cyclospora cayetanensis*
- *Entamoeba histolytica*
- *Giardia lamblia*

### Meningitis/Encephalitis


- Targets not among most likely pathogens
- Use based on clinical presentation

\*Bacterial culture still needed for AST, submission to PH

- Consider use of smaller, targeted panels or single NAAT assays




# ADLM GUIDANCE DOCUMENT ON LABORATORY DIAGNOSIS OF RESPIRATORY VIRUSES



# LABORATORY TESTING FOR INFECTIOUS CAUSES OF DIARRRHEA

## MAYO CLINIC LABORATORIES




Warning signs and risk factors for severe disease include **fever**, bloody diarrhea, dysentery, severe abdominal pain, dehydration, hospitalization, and immunocompromise



# MENINGITIS/ENCEPHALITIS ALGORITHM

## MAYO CLINIC LABORATORIES





# 2


## **CASE DESCRIPTION**

## CASE # 2

- A 37 y/o male returned from a 2-week trip to Colombia where he went hiking and backpacking in the jungle.
- He states that during the trip he had a short episode of loose stools.
- Two days after returning home to the U.S. he developed fever, headache and malaise.
- He has no appetite and feels unwell.
- On physical exam he is febrile to 39° C, his HR is 60 and his BP is 100/60. His exam is otherwise normal with no hepatosplenomegaly.
- Laboratory findings include pancytopenia and elevated liver enzymes.

# CASE #2 LABORATORY WORKUP

- Broad differential
- Stool plated to BA, MAC, XLD
- Gastrointestinal NAAT panel performed
  - *Salmonella* sp.
- Gram-negative bacilli on XLD after 2 days of incubation at 37° C.
  - XLD Red colonies with black center (H<sub>2</sub>S)
  - MAC no color
- *Salmonella* sp. identified by MALDI-TOF
- Reported to public health laboratory
  - Isolate submitted for serotyping



Salman HA et al. PMCID: PMC8404135

# CASE #2

## WHAT'S A LAB TO DO?



### Culture

- Selective or chromogenic media
  - MAC, S/S, HE, XLD, bismuth sulfate, enrichment broth
- TSI: K/A; H<sub>2</sub>S
- Consider turnaround time



### Serotyping

- Capsular antigen (Vi)
- Somatic antigen (O)
  - Serogroup D
- > 2500 serotypes
- Generally performed at PH laboratories



### Antimicrobial Susceptibility Testing

- Only for invasive and typhoidal isolates
- See CLSI M-100
- AM, CIP, LVX, SXT, CRO, CTX, AZM
- XDR emerging (Middle East, SE Asia)

# CASE #2

## WHAT'S A LAB TO DO?



### MALDI-TOF

- Need pure culture isolate
- ID as *Salmonella* sp. (genus level)
- Database dependent



### Molecular

- Multiplex GI NAAT performed direct from specimen
- *Salmonella* sp. (*enterica* and *bongori*)
- Subtypes Typhi and Paratyphi included
- NGS for strain typing



### Reporting

- Reportable to Public Health
  - PulseNet
- Organism needed for PH submittal

# CASE RESOLUTION

- Identified by public health laboratory by WGS as
  - *Salmonella enterica* subsp. *enterica* serotype Typhi
  - O antigen Serogroup D
- *Salmonella enterica*
  - Six subtypes (I – VI)
- AST results (primary agents): All susceptible
  - Ampicillin
  - Ciprofloxacin/Levofloxacin
  - TMP/SFX
  - Cefotaxime/ceftriaxone
- Emergence of XDR strains with resistance to all first-line agents
  - Pakistan/Iraq; consider carbapenem or azithromycin

<https://stacks.cdc.gov/view/cdc/102640.Feb 12, 2021>



3

# **CASE DESCRIPTION**



# CASE # 3

- A 5 y/o boy travelled to Italy with his parents to visit friends that live near Milan. They stayed for 5 days.
- Three days after returning the parents noticed that he had a runny nose and a cough. He developed high fever the next day as well as bilateral conjunctivitis.
- He felt unwell and had no appetite.
- Approximately two days later the mother noticed a rash that was mostly in the hairline and behind the ears.
- On physical exam he is febrile to 38.8° C and tachycardic. He has bilateral conjunctivitis and a maculopapular rash in the face and upper body.
- Laboratory findings include leukopenia with lymphopenia and elevated liver enzymes.
- Mother states that she has her family do not believe in vaccines.

# CASE #3

## -WHAT'S A LAB TO DO?

- Infectious differential (just a few)

Viruses causing rash	Bacteria causing rash
EBV, VZV	<i>Neisseria meningitidis</i>
Primary HIV	Staphylococcal toxic shock
Parvovirus B19	Rickettsial infections
Enterovirus	Typhoid fever

- NP swab submitted for culture and NAAT
  - All analytes negative by respiratory panel
  - Inoculate blood and respiratory cultures
- Clinical presentation can aid diagnosis and guide isolation

Wu HM.Semin Diagn Pathol. 2019 May;36(3):197-202.

# MORE INFORMATION COMES TO THE LAB....



- Patient presentation:
  - Had conjunctivitis, cough, and coryza for 7 days
  - Maculopapular rash on the upper body
  - Unable to confirm vaccination history
- Clinical presentation and history suggests.....

**Measles**

# OPTIONS FOR MEASLES (RUBEOLA) TESTING

- Reportable disease – communicate with your PH lab first for assistance
  - 90% infection rate in susceptible populations
- Identify – Isolate – Inform
  - Handle specimens carefully!
- RT-PCR
  - NP swab, throat swab within 5 days of rash onset
  - Urine within 6-14 days of rash onset
  - Available from public health laboratories, some commercial reference laboratories
  - Laboratory-developed tests could be an option
  - No commercial FDA-approved test available
  - **Measles not included on syndromic NAAT panels**
- Serologic detection of measles IgM
  - Useful for confirmation
  - Negative in early disease
  - Available from public health laboratories, some commercial reference laboratories



# ESOTERIC TESTING FOR TRAVEL ASSOCIATED PATHOGENS

# “TROPICAL FEVER” SYNDROMIC PANELS

## BIOFIRE® FILMARRAY® TROPICAL FEVER (TF) PANEL

- *Leptospira* sp. (Group 1)
- Chikungunya
- Dengue
  - Serotypes 1,2,3,4 grouped together
- *Plasmodium* sp.
  - *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae*, and *P. knowlesi*
- *Plasmodium falciparum*
- *Plasmodium vivax/ovale*
- Specimen: 200 microliters whole blood (EDTA)



# TF ASSAY PERFORMANCE

- From IFU: “Evaluation for more common causes of febrile illness should be considered prior to evaluation with this panel”
- Qualitative results only
  - Quantitation of *Plasmodium* sp. requires smear
- PCR may over diagnose disease in patients from endemic areas

Target	N (pos/neg)	PPA%	NPA%
<i>Leptospira</i> sp.	16/1859	93.8	99.8
Chikungunya	25/1850	100	99.9
Dengue (1-4)	283/1592	94.0	100
<i>Plasmodium</i> sp.	345/1530	98.3	99.2
<i>P. falciparum</i>	248/1627	92.7	99.8
<i>P. vivax/ovale</i>	124/1751	92.7	99.8

# OTHER ESOTERIC TESTS

## *HOW TO GET THESE DONE?*

- Consider turnaround time and need for clinical intervention
- Serology
  - State PH labs/CDC – check test availability
  - Commercial reference labs
- Other NAAT testing
  - State PH labs/CDC – check test availability
  - Commercial reference labs
- Role of NGS
  - Availability
  - Turnaround time
- Viral culture
  - Few performing laboratories; potentially hazardous
- Develop an LDT?

Consider what  
you will do before  
it happens



# LABORATORY COMMITMENT IF ESOTERIC TESTING PERFORMED

Purchase of test platform

Test verification/  
validation

Training and  
competency of  
staff

Proficiency  
testing

Quality  
control/quality  
assurance

Reagent  
inventory  
management

Laboratory  
workflow

- Random access?
- Once per day?
- Once per week?
- What shift?

# GENERAL TESTING COMMENTS

# LABORATORY BIOSAFETY

- May evolve based on identification of pathogen
- Standard PPE
  - Impermeable gown/lab coat
  - Gloves
  - Additional respiratory protection depending on pathogen
- Use of BSC for specimen manipulation
  - Inoculation of culture plates
  - Creating smears
  - NAAT inoculation
- Use of automated test systems
  - Follow manufacturer recommendations for cleaning and disinfection
- Biohazardous waste disposal



# LABORATORY WORKFLOW

- Consider scenarios ahead of time
  - *What might you be likely to see?*
  - Institution and laboratory drills
- Develop plans through collaboration
  - Infectious Disease
  - Infection Control
  - Clinical services (ED, outpatient)
- Consider what testing is feasible for your laboratory practice
  - Academic or referral center?
  - Small hospital or community hospital?
  - Nature of patient population



HCID Drill June 2025

# COMMUNICATION OF FINDINGS

- Critical/alert value?
- Infection control considerations
- Notification of Public Health
- Key Groups
  - Infectious Disease
  - Infection Prevention
  - Who are your contacts?
- High Consequence Infectious Disease plan?
- Plan for laboratory handling of biological agents?



# RESOURCES

- State PH laboratories and CDC
- CDC Yellow Book
  - <https://www.cdc.gov/yellow-book/index.html>
- WHO
  - <https://www.who.int/emergencies/disease-outbreak-news>
- GeoSentinel
  - [https://geosentinel.org/alerts/?post\\_type=alert&s=2025](https://geosentinel.org/alerts/?post_type=alert&s=2025)
  - Membership required
- ProMED
  - <https://www.promedmail.org>
  - Membership required



**THANK YOU AND SAFE TRAVELS!**